Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence

Urology

Volumn 60, Issue 6, 2002, Pages 1034-1039

  Gretzer, Matthew B ^a,b   Epstein, Jonathan I ^a   Pound, Charles R ^a,c   Walsh, Patrick C ^a   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; STRATIFICATION;

AGED; BIOPSY; CONFIDENCE INTERVALS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERENCE VALUES; TIME FACTORS;

EID: 0036900782     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01997-0     Document Type: Article

References (28)

1. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen a decade of discovery - what we have learned and where we are going . J Urol. 162:1999;293-306.
2. Greenlee R.T., Hill-Harmon M.B., Murrey T., et al. Cancer statistics, 2001. CA Cancer J Clin. 51:2001;15-36.
3. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 58:2001;843-848.
4. Stephenson R. Population-based prostate cancer trends in the PSA era data from the Surveillance, Epidemiology, and End Results (SEER) program . Mongr Urol. 19:1998;1-19.
5. Han M., Partin A., Piantadosi S., et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 166:2001;416-419.
6. Pound C.R., Partin A.W., Eisengerger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
7. Partin A.W., Piantadosi S., Sanda M.G., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 45:1995;831-838.
8. Dillioglugil O., Leibman B.D., Kattan M.W., et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 50:1997;93-99.
9. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy the 15-year Johns Hopkins experience . Urol Clin North Am. 28:2001;555-565.
10. Gerber G.S., Thisted R.A., Scardino P.T., et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 276:1996;615-619.
11. Benson RC Jr, Tomera KM, Zincke H, et al: Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J Urol 131: 1103-1106, 1984.
12. Lange P.H., Ercole C.J., Lightner D.J., et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 141:1989;873-879.
13. Frazier H.A., Robertson J.E., Humphrey P.A., et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 149:1993;516-518.
14. D'Amico A.V., Whittington R., Schultz D., et al. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 158:1997;1422-1426.
15. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer a multi-institutional update . JAMA. 277:1997;1445-1451.
16. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy . Int J Radiat Oncol Biol Phys. 37:1997;1043-1052.
17. Zietman A.L. Radical prostatectomy for adenocarcinoma of the prostate the influence of preoperative and pathologic findings on biochemical disease-free outcome . Urology. 43:1994;828-833.
18. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 90:1998;766-771.
19. D'Amico A.V., Whittingham R., Malkowicz S.B., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 166:2001;2185-2188.
20. D'Amico A.V. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Huntingt). 15:2001;1049-1075.
21. Blute M.L., Bergstralh E.J., Partin A.W., et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 164:2000;1591-1595.
22. Bauer J.J., Connelly R.R., Seterhenn I.A., et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer. 79:1997;952-962.
23. Lerner S.E., Blute M.L., Bergstraln E.J., et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 156:1996;137-143.
24. Banerjee M., Biswas D., Sakr W., et al. Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma. Cancer. 89:2000;404-411.
25. Cheung R., Altschuler M.D., D'Amico A.V., et al. ROC optimization may improve risk stratification of prostate cancer patients. Urology. 57:2001;286-290.
26. Epstein J.I., Walsh P.C., Carmichael M. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA. 271:1994;368-373.
27. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 18:2000;1164-1172.
28. Freedland S.J., Csathy G.S., Frederick D., et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 167:2002;516-520.